Table 1.
Patients and disease characteristics.
| Variable | N = 298 1 |
|---|---|
| Age | 62 (55, 69) |
| Sex | |
| Female | 99 (33%) |
| Male | 199 (67%) |
| Tobacco status | |
| Former Smoker | 140 (47%) |
| Non smoker | 36 (12%) |
| Smoker | 122 (41%) |
| Brain metastases | 72 (29%) |
| Performance status | |
| ≥2 | 26 (8.9%) |
| 0–1 | 265 (91%) |
| Mutation profile | |
| ALK | 1 (0.8%) |
| BRAF | 9 (7.4%) |
| EGFR | 14 (11%) |
| KRAS | 87 (71%) |
| Other mutation | 5 (4.1%) |
| ROS1 | 2 (1.6%) |
| Wild type | 4 (3.3%) |
| Immunotherapy type | |
| anti-CTLA-4 | 3 (1.0%) |
| anti-PD-1 | 266 (89%) |
| anti-PD-L1 | 26 (8.7%) |
| Combination | 3 (1.0%) |
| Previous treatment | |
| Chemotherapy | 281 (95%) |
| Chemotherapy + immunotherapy | 5 (1.7%) |
| Targeted therapy | 11 (3.7%) |
| Response | |
| Complete response | 2 (0.7%) |
| Partial response | 44 (15%) |
| Progressive disease | 131 (45%) |
| Stable disease | 113 (39%) |
1 Median (inter-quartile range); n (%).